Amarin Corporation plc (ADR) (NASDAQ:AMRN) was in 18 hedge funds' portfolio at the end of the fourth quarter of 2012.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) stock gained 3.95% to $7.10. The company, on May 9, announced financial results for the quarter ended March 31, 2013 and provided an update on company operations.

Editor's Note: Related Tickers: Amarin Corporation plc (ADR) (NASDAQ:AMRN), GlaxoSmithKline plc (ADR) (NYSE:GSK), Abbott Laboratories (NYSE:ABT), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Obagi Medical Products, Inc. (NASDAQ:OMPI) ...

BEDMINSTER, N.J. and DUBLIN, Ireland, April 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...

Amarin Corporation plc (ADR) (NASDAQ:AMRN) stock gained 7.04% to $6.84. The company, on April 18, announced the approval of the Supplemental New Drug Application (sNDA) to the U.S.

AbbVie Inc (NYSE:ABBV) shares decreased 1.82% to $44.32. Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate ...

Amarin Corporation plc. (ADR)(NASDAQ:AMRN)slipped 2.14% and closed at $6.39 on a traded volume of 3.90 million shares.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) gained 6.15% at $7.25 after trading 5.96 million ADRs. It is a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.

Amarin Corporation plc. (ADR)(NASDAQ:AMRN) went down 2.92% and closed at $6.65 on a traded volume of 5.08 million shares.

Aruba Networks, Inc.(NASDAQ:ARUN) shares decreased 2.66% to $21.56. ARUN's stock was downgraded by research analysts at UBS AG from a �buy� rating to a �neutral� rating in a report released on April 4. They currently have a $0.78 target price on the ...